AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14963845 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurotest
Number of subjects: 60
Study 14963845 — intervention group
Group type: COMPARATOR
Intervention: 7MT (seven-minute test)
Number of subjects: 60
Study 14963845 — intervention group
Group type: COMPARATOR
Intervention: MMSE (mini-mental state examination)
Number of subjects: 60
Study 11414343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependent patients (older group)
Number of subjects: 226
Study 11414343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependent patients (younger group)
Number of subjects: 226
Study 11414343 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic controls (older group)
Number of subjects: 226
Study 11414343 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic controls (younger group)
Number of subjects: 226
Study 9565444 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment
Number of subjects: 154
Study 9565444 — intervention group
Group type: COMPARATOR
Intervention: Rescue surfactant treatment
Number of subjects: 154
Study 7932936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital rehabilitation (mean of 12.9 days)
Number of subjects: 100
Study 7932936 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory rehabilitation (mean of 11.9 days)
Number of subjects: 100
Study 7932936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital rehabilitation
Number of subjects: 100
Study 7932936 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory rehabilitation
Number of subjects: 100
Study 2905241 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg once daily
Number of subjects: 363
Study 2905241 — intervention group
Group type: COMPARATOR
Intervention: roxatidine acetate 75 mg twice daily
Number of subjects: 363
Study 31010570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical menthol at different concentrations (liquid and gel formulations)
Number of subjects: 59
Study 29415829 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric
Number of subjects: 71
Study 29415829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 25245138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase perceived control (PC)
Number of subjects: 185
Study 25245138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase intrinsic motivation (IM)
Number of subjects: 185
Study 25245138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to decrease perceived control (PC)
Number of subjects: 185
Study 25245138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase extrinsic motivation
Number of subjects: 185
Study 25245138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interventions to increase PC and IM
Number of subjects: 185
Study 24093664 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/mL hyaluronic acid gel (VYC-20L)
Number of subjects: 282
Study 24093664 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 282
Study 21756794 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of compound artificial bone of HA-Bone cement
Number of subjects: 40
Study 21756794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implantation)
Number of subjects: 40
Study 19131469 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive weekly automated telephone self-management support with nurse follow-up (ATSM)
Number of subjects: 339
Study 19131469 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly group medical visits with physician and health educator facilitation (GMV)
Number of subjects: 339
Study 19131469 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 339
Study 16359822 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol challenge test (estradiolbenzoate 0.04 mg/kg, intramuscular injection)
Number of subjects: 25
Study 15650497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg-60 mg daily for up to 19 weeks)
Number of subjects: 96
Study 11269568 — intervention group
Group type: EXPERIMENTAL
Intervention: A/L/Z combination tablet after an overnight fast
Number of subjects: 24
Study 11269568 — intervention group
Group type: COMPARATOR
Intervention: Abacavir 300 mg + Lamivudine 150 mg + Zidovudine 300 mg tablets after an overnight fast
Number of subjects: 24
Study 11269568 — intervention group
Group type: EXPERIMENTAL
Intervention: A/L/Z combination tablet 5 minutes after a standardized high-fat breakfast
Number of subjects: 24
Study 9204091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 680
Study 9204091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel
Number of subjects: 680
Study 8135618 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to participate in a trial
Number of subjects: 541
Study 8135618 — intervention group
Group type: COMPARATOR
Intervention: Refusal to participate in a trial
Number of subjects: 541
Study 8135618 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between parents
Number of subjects: 541
Study 8135618 — intervention group
Group type: COMPARATOR
Intervention: Reasons for refusal
Number of subjects: 541
Study 8135618 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of mothers who consented
Number of subjects: 541
Study 8135618 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level of consent group
Number of subjects: 541
Study 2883988 — intervention group
Group type: EXPERIMENTAL
Intervention: H-I 42 BS 50 mg
Number of subjects: 17
Study 2883988 — intervention group
Group type: EXPERIMENTAL
Intervention: H-I 42 BS 100 mg
Number of subjects: 17
Study 2883988 — intervention group
Group type: EXPERIMENTAL
Intervention: H-I 42 BS 200 mg
Number of subjects: 17
Study 2883988 — intervention group
Group type: EXPERIMENTAL
Intervention: H-I 42 BS 400 mg
Number of subjects: 17
Study 2883988 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 17
Study 2883988 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 17
Study 2883988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2883988 — intervention group
Group type: EXPERIMENTAL
Intervention: H-I 42 BS 400 mg vs Atenolol 50 mg
Number of subjects: 17
Study 31283891 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical CHQ 0.03% twice a day with carboxymethylcellulose (CMC) 0.5% three times a day
Number of subjects: 150
Study 31283891 — intervention group
Group type: COMPARATOR
Intervention: Topical CMC 0.5% three times a day
Number of subjects: 150
Study 28864027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg plus ivermectin 200 μg/kg
Number of subjects: 636
Study 28864027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg plus oxantel pamoate 25 mg/kg
Number of subjects: 636
Study 28864027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg plus placebo (monotherapy)
Number of subjects: 636
Study 28864027 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 400 mg plus oxantel pamoate 25 mg/kg
Number of subjects: 636
Study 27755601 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention using misoprostol (600 mcg)
Number of subjects: 0
Study 27755601 — intervention group
Group type: COMPARATOR
Intervention: Secondary prevention using misoprostol
Number of subjects: 0
Study 27755601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of primary prevention
Number of subjects: 0
Study 27755601 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis of secondary prevention
Number of subjects: 0
Study 24530023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intracameral injection of 1.2 mg/0.03 mL of triamcinolone acetonide
Number of subjects: 60
Study 24530023 — intervention group
Group type: COMPARATOR
Intervention: Postoperative oral prednisolone (1 mg/kg per day for 15 days, tapered over 2 weeks)
Number of subjects: 60
Study 22866670 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous PRP injection with rehabilitation programme
Number of subjects: 28
Study 22866670 — intervention group
Group type: COMPARATOR
Intervention: rehabilitation programme only
Number of subjects: 28
Study 20804229 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation devices
Number of subjects: 0
Study 20804229 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacements
Number of subjects: 0
Study 20804229 — intervention group
Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 0
Study 20804229 — intervention group
Group type: COMPARATOR
Intervention: Pain, functioning, and QoL
Number of subjects: 0
Study 17893257 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic exercise 45 min/session, 300 Kcal/day and muscle strength training 20 min/session, 100 Kcal/day, five times per week for 12 weeks)
Number of subjects: 48
Study 15047594 — intervention group
Group type: EXPERIMENTAL
Intervention: Smelling strawberry
Number of subjects: 0
Study 15047594 — intervention group
Group type: COMPARATOR
Intervention: Smelling ham
Number of subjects: 0
Study 15047594 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined odors
Number of subjects: 0
Study 12431940 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunkimmune (hypothetical drug)
Number of subjects: 0
Study 12431940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 11228858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker implantation
Number of subjects: 20
Study 11228858 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 20
Study 7582390 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC-1304
Number of subjects: 0
Study 7582390 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 2924158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic anesthesia
Number of subjects: 8
Study 2924158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 518108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid daily supplement from age 2 months
Number of subjects: 0
Study 518108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31442204 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) in addition to conventional pharmacological treatment with Indacaterol-Glycopyrronium
Number of subjects: 32
Study 31442204 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacological treatment with Indacaterol-Glycopyrronium
Number of subjects: 32
Study 28919126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (2 mSv)
Number of subjects: 3074
Study 28919126 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (≤8 mSv)
Number of subjects: 3074
Study 26343746 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentors trained in positively deviant behaviors regarding childhood obesity
Number of subjects: 60
Study 26343746 — intervention group
Group type: COMPARATOR
Intervention: Community health workers delivering health education on obesity‐related behaviors
Number of subjects: 60
Study 26343746 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentors
Number of subjects: 60
Study 24995688 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BoNT‐A)
Number of subjects: 27
Study 24995688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fruit and vegetable juice powder concentrate
Number of subjects: 0
Study 22383296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19295227 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy intervention
Number of subjects: 18
Study 19295227 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 48)
Number of subjects: 18
Study 18063846 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG (group B)
Number of subjects: 22
Study 18063846 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG (group A)
Number of subjects: 22
Study 15235718 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE-mo (modified Mini-Mental State Examination)
Number of subjects: 232
Study 15235718 — intervention group
Group type: COMPARATOR
Intervention: MMSE-ad (adapted Mini-Mental State Examination)
Number of subjects: 232
Study 11173147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment kinetic parameter LI (labeling index)
Number of subjects: 0
Study 11173147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment Tpot measurements using flow cytometry
Number of subjects: 0
Study 11173147 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry measuring LI
Number of subjects: 0
Study 9745996 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide hemofiltration
Number of subjects: 0
Study 8042760 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of tramadol (100 mg loading dose, 12 mg/h for 24 h)
Number of subjects: 135
Study 8042760 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of tramadol
Number of subjects: 135
Study 8042760 — intervention group
Group type: COMPARATOR
Intervention: Repetitive bolus administration (placebo infusion)
Number of subjects: 135
Study 8042760 — intervention group
Group type: COMPARATOR
Intervention: Repetitive bolus administration
Number of subjects: 135
Study 8042760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study 2179363 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mortality (0-3 months)
Number of subjects: 515
Study 2179363 — intervention group
Group type: EXPERIMENTAL
Intervention: Late mortality (3-12 months)
Number of subjects: 515
Study 2179363 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk of early mortality compared to late mortality
Number of subjects: 515
Study 2179363 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for early mortality
Number of subjects: 515
Study 2179363 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for late mortality
Number of subjects: 515
Study 600634 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor recall (performing the movements)
Number of subjects: 16
Study 600634 — intervention group
Group type: COMPARATOR
Intervention: Verbal recall (describing the movements)
Number of subjects: 16
Study 31578627 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlative Image Enhancement (CIE)
Number of subjects: 27
Study 31578627 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal children with no seizure history)
Number of subjects: 27
Study 31578627 — intervention group
Group type: EXPERIMENTAL
Intervention: CIE
Number of subjects: 27
Study 31176137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociation induction (n = 25)
Number of subjects: 50
Study 31176137 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 25)
Number of subjects: 50
Study 28918594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at the knee (KP)
Number of subjects: 891
Study 28918594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at the knee and other sites (KOP)
Number of subjects: 891
Study 28918594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at other sites (OP)
Number of subjects: 891
Study 26437320 — intervention group
Group type: EXPERIMENTAL
Intervention: CC ointment (CCO)
Number of subjects: 17
Study 26437320 — intervention group
Group type: COMPARATOR
Intervention: hydrogel
Number of subjects: 17
Study 26437320 — intervention group
Group type: EXPERIMENTAL
Intervention: CC or CC digests of collagen type I or III
Number of subjects: 17
Study 23626984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia implants supporting maxillary four-implant overdentures and mandibular three-implant overdentures; 28 implants total (maxilla: 16, mandible: 12)
Number of subjects: 4
Study 23626984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia implants
Number of subjects: 4
Study 22256638 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Ashi-points group (group A)
Number of subjects: 68
Study 22256638 — intervention group
Group type: COMPARATOR
Intervention: Ashi-points group (group B)
Number of subjects: 68
Study 20048529 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 101
Study 20048529 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 101
Study 20048529 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 101
Study 18557003 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc 'O' Sit cushions used by 31 students in the treatment group for a 2-week period.
Number of subjects: 63
Study 18557003 — intervention group
Group type: COMPARATOR
Intervention: Control group of 32 students not using the Disc 'O' Sit cushions.
Number of subjects: 63
Study 15159224 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy-dense entrée (7.32 kJ/g) served in the largest portion (900 g)
Number of subjects: 39
Study 15159224 — intervention group
Group type: COMPARATOR
Intervention: Lower energy-dense entrée (5.23 kJ/g) served in the smallest portion (500 g)
Number of subjects: 39
Study 11454878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² as a 1-hour infusion every 4 weeks
Number of subjects: 474
Study 11454878 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m²/d for 5 consecutive days every 3 weeks
Number of subjects: 474
Study 11454878 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD in platinum-sensitive patients
Number of subjects: 474
Study 11454878 — intervention group
Group type: COMPARATOR
Intervention: Topotecan in platinum-sensitive patients
Number of subjects: 474
Study 11454878 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 474
Study 9741512 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (digoxin, diuretic, ACEI)
Number of subjects: 266
Study 9741512 — intervention group
Group type: COMPARATOR
Intervention: Digoxin and diuretic therapy
Number of subjects: 266
Study 9741512 — intervention group
Group type: COMPARATOR
Intervention: ACEI and diuretic therapy
Number of subjects: 266
Study 9741512 — intervention group
Group type: COMPARATOR
Intervention: Diuretic alone
Number of subjects: 266
Study 7989963 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-crystal aluminum ceramic (S)
Number of subjects: 5
Study 7989963 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycrystal aluminum ceramic (P)
Number of subjects: 5
Study 7989963 — intervention group
Group type: COMPARATOR
Intervention: Control dentin specimen (D)
Number of subjects: 5
Study 3055943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (50 mg, tid)
Number of subjects: 48
Study 3055943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30495974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4532
Study 30341966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 50
Study 30341966 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 50
Study 27418571 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stressed dapagliflozin 2.5-mg tablets
Number of subjects: 57
Study 27418571 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stressed dapagliflozin 10-mg tablets
Number of subjects: 57
Study 27418571 — intervention group
Group type: COMPARATOR
Intervention: Heat-stressed dapagliflozin 2.5-mg tablets (fed state)
Number of subjects: 57
Study 27418571 — intervention group
Group type: COMPARATOR
Intervention: Heat-stressed dapagliflozin 10-mg tablets (fed state)
Number of subjects: 57
Study 24566560 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based 12-week weight loss intervention (PREMIER with DASH diet)
Number of subjects: 36
Study 24566560 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 22808048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) alone
Number of subjects: 151
Study 22808048 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) plus unobserved primaquine for either 5 days or 14 days
Number of subjects: 151
Study 22808048 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of P.vivax
Number of subjects: 151
Study 20663239 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing Better Living for Elders (ABLE) intervention providing compensatory strategies
Number of subjects: 148
Study 20663239 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing Better Living for Elders (ABLE) intervention
Number of subjects: 148
Study 17979895 — intervention group
Group type: EXPERIMENTAL
Intervention: ASM/body mass
Number of subjects: 189
Study 17979895 — intervention group
Group type: EXPERIMENTAL
Intervention: ASM/height(2)
Number of subjects: 189
Study 15309493 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material with iodine concentration of 300 mg/ml
Number of subjects: 70
Study 15309493 — intervention group
Group type: COMPARATOR
Intervention: Contrast material with iodine concentration of 370 mg/ml
Number of subjects: 70
Study 12200512 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeNet hotline services (part of Project Liberty) providing free education, outreach, and crisis counseling.
Number of subjects: 0
Study 12200512 — intervention group
Group type: COMPARATOR
Intervention: Project Liberty media campaign
Number of subjects: 0
Study 10182115 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure (MAP) during cardiopulmonary bypass (CPB); low-flow corrected CPB MAP of 77.7 +/- 7.1 mmHg
Number of subjects: 248
Study 10182115 — intervention group
Group type: COMPARATOR
Intervention: Lower mean arterial pressure (MAP) during cardiopulmonary bypass (CPB); low-flow corrected CPB MAP of 56.7 +/- 5.0 mmHg
Number of subjects: 248
Study 8092097 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (60 mg/d)
Number of subjects: 20
Study 8092097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2690838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 80
Study 2690838 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with hydroxyethyl starch (HAES) and naftidrofuryl
Number of subjects: 80
Study 30844881 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation
Number of subjects: 34